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OBJECTIVE — The purpose of this study was to evaluate the effect of telephonic care man-
agement within a diabetes disease management program on adherence to treatment with hypo-
glycemic agents, ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), statins, and
recommended laboratory tests in a Medicaid population.
RESEARCH DESIGN AND METHODS — A total of 2,598 patients with diabetes en-
rolled for at least 2 years in Florida: A Healthy State (FAHS), a large Medicaid disease manage-
ment program, who received individualized telephonic care management were selected if they
were eligible for at least 12 months before and 12 months after beginning care management.
Patients were matched one-to-one on all baseline characteristics to 2,598 control patients. The
impact of care management on utilization and adherence rates for diabetes-related medications
and tests was analyzed with the difference-in-difference estimator.
RESULTS — Changes in utilization were evaluated separately for those who were character-
ized as adherent to treatment at baseline (“users”) and those who were not (“nonusers”). Both
groups achieved signiﬁcant improvement in adherence between baseline and follow-up. Non-
users increased their overall hypoglycemic use by 0.7 script (P  0.001), by 0.7 script for ACEIs
and statins (both P  0.001), by 0.8 test for A1C (P  0.001), and by 0.7 test for lipids (P 
0.001).Usersincreasedhypoglycemicuseby1.5scripts(P0.001)andinsulinuseby0.9script
(P  0.001).
CONCLUSIONS — The FAHS telephonic care management intervention effectively in-
duced Medicaid patients with diabetes to begin treatment and improved adherence to oral
hypoglycemic agents and recommended tests. It also substantially improved adherence among
baseline insulin users.
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L
ifelongtreatmentadherenceandlife-
style modiﬁcation are recognized as
the most critical components of dia-
betesmanagement.Anumberofrandom-
ized clinical trials provide evidence that
medication adherence and adherence to
recommended tests and services can ef-
fectively reduce complications and im-
prove patient outcomes (1,2). Other
studies have shown that adherence to
medications, tests, and services is associ-
ated with decreased hospitalizations,
complications, and costs among individ-
uals with type 2 diabetes (3). Yet many
patients fail to comply with recom-
mended treatment guidelines (4,5). A re-
cent meta-analysis suggested that mean
adherence to treatment recommenda-
tions for patients with diabetes is only be-
tween 58 and 75% (6).
Patient-centered interventions, such
as disease management programs, can be
used to improve adherence. They have
been implemented to educate the chron-
ically ill and to facilitate the management
of their diseases (7). Their primary pur-
poseistomonitoradherencetoevidence-
basedtreatmentrecommendationsandto
support the self-management skills to
achieve adherence (8). There is evidence
thatdiseasemanagementcanimprovethe
short-term processes of care, including
medication adherence (9) and regular
A1C and lipid testing (10).
To our knowledge, there are few
published studies that examined the as-
sociation between disease management
program participation and adherence to
medications and preventive health pro-
tocols in a Medicaid population (10).
Medicaid populations and speciﬁcally
beneﬁciaries with chronic conditions
often have unique health care needs.
Most beneﬁciaries have multiple
chronic physical and behavioral health
conditions, often complicated by difﬁ-
cult socioeconomic stressors (11). Ben-
eﬁciaries with chronic conditions use
health care and health-related services
more frequently. Their care is on aver-
age more costly than that for beneﬁcia-
ries without chronic conditions (11). A
decreased ability to obtain timely, ap-
propriate care and maintain continuity
(12,13) contribute to these trends.
In this analysis we used data from the
Florida: A Healthy State (FAHS) disease
management program to assess the im-
pact of educating Medicaid beneﬁciaries
about their chronic diseases and increas-
ing their self-management abilities. We
evaluated whether a guideline-driven
comprehensive disease management pro-
gram can improve the use of diabetes-
related recommended tests, services, and
medications among Medicaid Primary
Care Case Management (PCCM) beneﬁ-
ciaries with diabetes.
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FAHS
In 2001, Florida’s Agency for Health Care
Administration (AHCA) and Pﬁzer part-
nered to create a statewide disease man-
agement program to address multiple
chronicdiseases.Thedurationofthispro-
gramwasmorethan5years,betweenJuly
2001 and December 2006. A detailed ex-
planation of the program’s design, inter-
vention and methods, and operations has
been published elsewhere (14). Initially
designedasa2-yearpilot,FAHSprovided
education and support to PCCM Medic-
aid beneﬁciaries. This clinically and
ﬁnancially successful program was ex-
tended for 2 more years in 2003 and sub-
sequently transitioned to a new phase in
2005, led by the state, with Pﬁzer provid-
ing technical and program support.
Brieﬂy, AHCA and Pﬁzer designed a tele-
phonic disease management model that
reinforced goals already established be-
tween the health professional and patient
to prevent exacerbations of chronic ill-
ness,supportlifestylechange,andreduce
the ﬁnancial burden that chronic illness
places on Florida’s Medicaid program.
Only PCCM program participants with
diabetes, heart failure, hypertension, or
asthma were eligible for FAHS. AHCA
identiﬁed these individuals and assigned
a risk score (based on proprietary algo-
rithms developed by outside vendors)
reﬂecting clinical severity and the likeli-
hood of incurring high medical costs.
Note that these algorithms were based on
claims only and were therefore not af-
fected by changes in guidelines related to
cholesterolorbloodpressurelevels.Mod-
erate- and high-risk beneﬁciaries were re-
cruited for telephonic care management.
All beneﬁciaries, including those at low
risk, received low-literacy health educa-
tion mailings and had access to a 24-h
nurse call center.
The comprehensive telephonic care
management model used in FAHS was
delivered by nurse care managers respon-
sible for tailoring treatment plans to
each patient (14). Care managers used a
Web-based decision support application
offering guideline-recommended treat-
mentsandscreenings.Adherencetomed-
ications and staying current on all
recommended tests and services were
emphasized. Care managers inﬂuenced
adherence in at least four ways. They en-
couraged patients to follow through on
the provider’s orders and helped patients
problem solve adherence issues. Nurses
contacted the provider’s ofﬁce directly
with information that might result in a
new medication or test order. They sent
laboratory kits directly to the patients to
ensure that the results were available.
Care managers also had an indirect inﬂu-
ence on adherence to guidelines by edu-
cating and empowering patients to
partner with their providers.
Analysis population
This analysis was limited to patients with
diabetes enrolled in FAHS. Over the
5-year life of the program, 24,979 (13%)
program participants had diabetes. Of
these individuals, 7,517 (30%) were of
moderate or high risk. As such, they were
eligible to participate in the telephonic
care management component of the pro-
gram. Patients could opt out of care man-
agement voluntarily. The ﬁnal sample
consisted of 2,598 individuals who did
not decline care management and were
enrolled in FAHS for at least 12 months
before participating in care management
andatleast12monthsafterinitiatingcare
management.
These 2,598 beneﬁciaries were
matched 1-to-1 to a control group of
moderate- to high-risk beneﬁciaries with
diabetes who were never care managed in
the program. Beneﬁciaries in both the
treatment and control groups were con-
tinuously eligible for FAHS for at least 2
years.Amongthetreatmentgroup,thein-
dex date was the day care management
began. A random observation window of
2 years was used for those in the control
group. For them, the index date was sim-
ply the midpoint of this 2-year interval.
These 2 years could be any continuous
period between January 2002 and De-
cember 2006.
Outcome measures
In this research we considered several
types of outcome measures: changes in
utilization and adherence with drugs rec-
ommended for diabetes treatment as well
as changes in patterns of annual labora-
tory tests. Hypoglycemic agents (both in-
sulin and oral antidiabetic drugs), statins,
ACE inhibitors (ACEIs), and angiotensin
receptorblockers(ARBs)wereconsidered
separately. Drug utilization and adher-
Table 1—Sample characteristics at baseline: demographics, comorbidities, non–drug health
care utilization
Group 1:
care managed
Group 2: not care
managed P value*
Demographics
Age (years) 52.8 51.1 0.001
Sex (% female) 78.3 70.0 0.001
Medicaid eligibility under
TANF 7.8 14.6 0.001
SSI 86.8 80.0 0.001
Both TANF and SSI 5.4 5.4 0.951
Race (%)
Black 25.8 24.2 0.189
Hispanic 5.7 5.7 0.905
White 35.5 38.1 0.066
Other 32.9 32.1 0.534
Comorbidities
Hypertension diagnosis (%) 16.7 11.4 0.001
Dyslipidemia diagnosis (%) 5.7 4.5 0.059
Sum Charlson index
conditions
0.6 0.4 0.001
Myocardial infarction (%) 0.6 0.3 0.101
Congestive heart failure (%) 2.8 0.8 0.001
Peripheral vascular (%) 1.2 0.6 0.020
Non–drug health care utilization
No. emergency room visits 1.4 1.3 0.474
No. inpatient stays 0.4 0.4 0.543
No. outpatient visits 10.8 9.3 0.001
No. other services 32.6 30.7 0.086
*
2 test or Student’s t test. SSI, Supplemental Security Income; TANF, Temporary Aid to Needy Families.
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classes of hypoglycemic agents (bigua-
nides, sulfonylureas, thiazolidinediones,
meglitinides, and insulin) and also for st-
atins, ACEIs, and ARBs. Drug utilization
wasmeasuredasthesumofdayssupplied
with a reﬁll in a particular drug class over
a period of 1 year pre- and post-index.
Adherence was measured with the medi-
cation possession ratio (MPR) (15). The
MPR was calculated as the sum of days
supplied, by class, over a 1-year period
divided by 365. The computation of an
MPR for overall hypoglycemic treatment,
including the combination of hypoglyce-
mic agents, was more complex. We as-
sumed that a prescription for a different
class of agents represented a switch to a
new class if the new prescription was
ﬁlled 90 days after that for the previous
drug. If the interval was shorter, the pa-
tient was assumed to be taking two drugs
simultaneously, and MPRs were aver-
aged. MPRs were simply added to each
other.Recommendedlaboratorytestsand
screening procedures (16,17) were also
evaluated. Laboratory codes were used to
identify A1C, lipid proﬁle, and mi-
croalbumin tests, and retinal examina-
tions were identiﬁed with CPT codes.
Their utilization was measured as a count
of the number of claims over 1 year.
Statistical analysis
To determine the impact of care manage-
ment, patients who were care managed
were compared with patients who were
notinacase-controlstudy.Toensurethat
both groups were similar, patients were
matched pairwise with a minimum dis-
tance estimator (18). Matching was based
on baseline characteristics including
health care utilization (i.e., health ser-
vices, laboratory, and pharmacy), comor-
bidity burden, age, sex, race, and
Medicaid enrollment status (Supplemen-
tal Security Income or Temporary Assis-
tance for Needy Families). Diagnoses
were used as a proxy for severity of dis-
ease and were combined to create a
Charlson comorbidity index (19). Pa-
tients in both groups had identical
health care beneﬁts and were treated
over the same period of time, thus elim-
inating the impact of changes in the
health care system, health care beneﬁts,
or treatment guidelines.
Our analysis proceeded in two steps.
First, we compared key baseline charac-
teristics (demographics, comorbidities,
and health care utilization) and baseline
useofglycemiccontrol,antihypertensive,
T
a
b
l
e
2
—
B
a
s
e
l
i
n
e
p
r
o
p
o
r
t
i
o
n
o
f
u
s
e
r
s
,
a
v
e
r
a
g
e
u
t
i
l
i
z
a
t
i
o
n
a
m
o
n
g
u
s
e
r
s
,
a
v
e
r
a
g
e
M
P
R
a
m
o
n
g
u
s
e
r
s
,
a
n
d
p
r
o
p
o
r
t
i
o
n
o
f
u
s
e
r
s
w
i
t
h
M
P
R
>
8
0
%
P
r
o
p
o
r
t
i
o
n
o
f
u
s
e
r
s
(
%
)
A
v
e
r
a
g
e
u
t
i
l
i
z
a
t
i
o
n
a
m
o
n
g
u
s
e
r
s
A
v
e
r
a
g
e
M
P
R
a
m
o
n
g
u
s
e
r
s
P
r
o
p
o
r
t
i
o
n
u
s
e
r
s
w
i
t
h
M
P
R

8
0
%
C
a
r
e
m
a
n
a
g
e
d
N
o
t
c
a
r
e
m
a
n
a
g
e
d
P
v
a
l
u
e
*
C
a
r
e
m
a
n
a
g
e
d
N
o
t
c
a
r
e
m
a
n
a
g
e
d
P
v
a
l
u
e
†
C
a
r
e
m
a
n
a
g
e
d
N
o
t
c
a
r
e
m
a
n
a
g
e
d
P
v
a
l
u
e
†
C
a
r
e
m
a
n
a
g
e
d
N
o
t
c
a
r
e
m
a
n
a
g
e
d
P
v
a
l
u
e
*
H
y
p
o
g
l
y
c
e
m
i
c
a
g
e
n
t
p
r
e
s
c
r
i
p
t
i
o
n
s
A
l
l
h
y
p
o
g
l
y
c
e
m
i
c
a
g
e
n
t
s
8
6
.
6
7
7
.
5

0
.
0
0
1
1
3
.
2
1
4
.
1

0
.
0
0
1
5
9
.
9
6
1
.
1
0
.
0
4
2
3
0
.
3
3
3
.
0
0
.
0
5
5
B
i
g
u
a
n
i
d
e
(
m
e
t
f
o
r
m
i
n
)
4
1
.
6
3
4
.
9

0
.
0
0
1
6
.
7
6
.
8
0
.
5
6
1
5
4
.
1
5
5
.
2
0
.
4
7
8
3
1
.
0
3
2
.
6
0
.
4
5
0
M
e
g
l
i
t
i
n
i
d
e
3
.
0
2
.
9
0
.
7
4
2
4
.
4
4
.
7
0
.
6
4
3
3
5
.
8
3
7
.
9
0
.
6
6
3
1
4
.
1
1
4
.
1
0
.
7
1
6
S
u
l
f
o
n
y
l
u
r
e
a
4
8
.
0
4
2
.
5

0
.
0
0
1
8
.
0
7
.
9
0
.
8
1
1
6
4
.
3
6
3
.
8
0
.
6
4
6
4
3
.
1
4
3
.
1
0
.
8
0
0
T
h
i
a
z
o
l
i
d
i
n
e
d
i
o
n
e
3
0
.
5
2
9
.
4
0
.
3
4
8
6
.
7
6
.
9
0
.
5
5
9
5
5
.
0
5
6
.
0
0
.
5
6
6
3
3
.
3
3
3
.
3
0
.
8
6
0
I
n
s
u
l
i
n
3
0
.
6
2
8
.
5
0
.
0
8
8
9
.
2
1
0
.
0
0
.
0
2
0
6
0
.
2
6
3
.
0
0
.
0
7
3
3
6
.
1
3
9
.
4
0
.
1
9
1
C
a
r
d
i
o
v
a
s
c
u
l
a
r
m
e
d
i
c
a
t
i
o
n
p
r
e
s
c
r
i
p
t
i
o
n
s
A
C
E
I
4
8
.
6
3
3
.
1

0
.
0
0
1
7
.
4
7
.
5
0
.
7
5
2
6
0
.
6
6
0
.
3
0
.
8
6
0
4
1
.
3
3
9
.
7
0
.
4
3
5
A
R
B
1
4
.
8
1
0
.
9

0
.
0
0
1
7
.
1
7
.
3
0
.
4
9
8
5
8
.
2
5
9
.
6
0
.
5
5
5
3
6
.
7
3
7
.
4
0
.
8
3
4
S
t
a
t
i
n
4
6
.
7
3
3
.
5

0
.
0
0
1
6
.
8
6
.
9
0
.
9
3
4
5
6
.
2
5
5
.
6
0
.
6
4
5
3
2
.
7
3
0
.
4
0
.
2
3
1
L
a
b
o
r
a
t
o
r
y
t
e
s
t
A
1
C
6
7
.
5
6
1
.
8

0
.
0
0
1
2
.
1
2
.
0
0
.
2
7
1
L
i
p
i
d
6
6
.
2
6
1
.
4

0
.
0
0
1
1
.
9
1
.
8
0
.
0
1
9
3
M
i
c
r
o
a
l
b
u
m
i
n
1
5
.
4
1
5
.
3
0
.
8
4
7
1
.
3
1
.
2
0
.
0
8
6
R
e
t
i
n
a
l
e
x
a
m
i
n
a
t
i
o
n
s
4
5
.
8
3
7
.
1

0
.
0
0
1
1
.
7
1
.
7
0
.
9
6
4
T
h
e
n
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
i
n
e
a
c
h
c
a
t
e
g
o
r
y
c
a
n
b
e
d
e
r
i
v
e
d
f
r
o
m
t
h
e
t
o
t
a
l
s
a
m
p
l
e
s
i
z
e
m
u
l
t
i
p
l
i
e
d
b
y
t
h
e
p
r
o
p
o
r
t
i
o
n
o
f
u
s
e
r
s
.
U
s
e
r
s
a
r
e
p
a
t
i
e
n
t
s
w
h
o
ﬁ
l
l
e
d
o
n
e
o
r
m
o
r
e
p
r
e
s
c
r
i
p
t
i
o
n
s
i
n
t
h
e
d
r
u
g
c
l
a
s
s
c
o
n
s
i
d
e
r
e
d
i
n
e
a
c
h
l
i
n
e
o
r
r
e
c
e
i
v
e
d
o
n
e
o
r
e
m
o
r
e
l
a
b
o
r
a
t
o
r
y
t
e
s
t
s
.
*

2
t
e
s
t
.
†
S
t
u
d
e
n
t
’
s
t
t
e
s
t
.
Thiebaud and Associates
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1719and antidyslipidemia agents and recom-
mended annual diabetes-related tests.
The second step evaluated changes over
time in two categories of patients: those
whoreportedusingdiabetes-relatedmed-
ications or tests at baseline (users) and
those who reported not using such drugs
ortestsatbaseline(nonusers).Userswere
deﬁned for each drug class (e.g., insulin,
thiazolidinediones, and statins) as pa-
tients who ﬁlled at least one prescription
at baseline. Nonusers were patients who
did not ﬁll any prescription in the drug
class considered. For tests, users were de-
ﬁned as patients who received a least one
testatbaseline.Changesinutilizationand
adherence were calculated as the differ-
ence between year 2 (follow-up) and year
1 (baseline) values. We compared the
changes in those care managed versus
those not care managed with the differ-
ence-in-differences estimator (20).
RESULTS—At baseline, care-managed
patients, although similar to never care-
managed patients (Table 1), were slightly
older (52.8 vs. 51.1 years; P  0.001),
more likely to be female (78.3 vs. 70.0%;
P  0.001), and more likely to be eligible
forMedicaidasSupplementalSecurityIn-
come beneﬁciaries (86.8 vs. 80.0%; P 
0.001). More care-managed patients re-
ceived a diagnosis of hypertension, con-
gestive heart failure, or peripheral artery
diseaseandhadslightlyhighercomorbid-
ityscores.Thesedifferencesaswellasdif-
ferences in race and most nondrug
utilization were small, although some-
times statistically signiﬁcant, and were
controlled for in our model.
Table 2 shows baseline values for
drug and laboratory test utilization (pro-
portion of users and average utilization
among users) and adherence with drug
treatment (as average MPR among users
and proportion of users with MPR
80%). Care-managed patients were
more likely to have used a hypoglycemic
agent, an ACEI, an ARB, or a statin at
baseline, although average utilization and
adherence were not signiﬁcantly different
betweengroups.Thesamepatternoccurred
with annual laboratory test utilization.
In the explanatory analysis, we quan-
tiﬁedimprovementsinutilizationandad-
herence with drug treatments separately
for baseline nonusers and users (Table 3).
It is important to realize that in this table
the impact of care management is mea-
sured by the change in utilization for pa-
tients receiving treatment relative to
control subjects—not relative to baseline
(group-speciﬁc values are available from
the authors). Care-managed patients re-
porting no utilization at baseline (nonus-
ers) were more likely to ﬁll prescriptions,
to maintain more days of supply, and to
have higher MPR than patients who were
not care managed. Care-managed pa-
tients ﬁlled an average of 0.7 script for
hypoglycemic agents (P  0.041), 0.7
script for ACEIs (P  0.001), and 0.7
script for statins (P  0.001) more than
non–care-managed patients. The in-
crease in days of supply and adherence
paralleled the rise in number of prescrip-
tions ﬁlled.
Care-managed patients reporting
some baseline utilization (users) achieved
asigniﬁcantincreaseinthenumberofﬁlls
and days’ supply of insulin, sulfonylurea,
and ACEI. There was also a signiﬁcant in-
crease in MPR, with the increase concen-
tratedintheinsulinclass.Comparedwith
baseline nonusers, who increased by only
a small amount of reﬁll and days’ supply
(0.1 ﬁll and 0.2 days’ supply) and
achieved a modest (1.3%) increase in
Table 3—Hypoglycemic and cardiovascular drugs: changes in utilization and adherence
Nonusers at baseline Users at baseline only
Care managed
vs. not care
managed P value
Care managed
vs. not care
managed P value
Number of ﬁlls*
Hypoglycemic drug prescriptions
All hypoglycemic agents 0.7 0.041 1.5 0.001
Biguanide (metformin) 0.5 0.001 0.1 0.548
Meglitinide 0.03 0.061 0.2 0.754
Sulfonylurea 0.6 0.001 0.3 0.02
Thiazolidinedione 0.2 0.005 0.3 0.109
Insulin 0.1 0.214 0.9 0.001
Cardiovascular medication
prescriptions
ACEI 0.7 0.001 0.3 0.02
ARB 0.2 0.001 0.4 0.107
Statin 0.7 0.001 0.06 0.676
Days supply*
Hypoglycemic drug prescriptions
All hypoglycemic agents 17.3 0.064 47.0 0.001
Biguanide (metformin) 14.6 0.001 3.4 0.439
Meglitinide 1.1 0.037 5.9 0.727
Sulfonylurea 17.9 0.001 11.1 0.009
Thiazolidinedione 6.7 0.005 8.9 0.104
Insulin 0.2 0.918 34.0 0.001
Cardiovascular medication
prescriptions
ACEI 22.3 0.001 9.9 0.018
ARB 5.7 0.001 11.0 0.102
Statin 19.2 0.001 1.8 0.646
MPR (% days covered)
Hypoglycemic drug prescriptions
All hypoglycemic agents 8.7 0.001 6.9 0.001
Biguanide (metformin) 4.5 0.001 0.4 0.740
Meglitinide 0.3 0.014 0.2 0.968
Sulfonylurea 5.7 0.001 1.3 0.231
Thiazolidinedione 2.4 0.001 1.0 0.488
Insulin 1.3 0.004 5.7 0.001
Cardiovascular medication
prescriptions
ACEI 6.2 0.001 4.3 0.685
ARB 1.3 0.001 0.7 0.7003
Statin 5.4 0.001 2.0 0.064
The difference-in-differences estimator was used here. Results are expressed as the change in utilization or
MPR in the care-managed group relative to the not–care managed group. *Over a 12-month period.
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their regimen (0.9 script and 34.0 days’
supply), resulting in a 5.7% increase in
MPR.
Next, we determined the impact of
care management on recommended labo-
ratory tests and retinal examinations (Ta-
ble 4). This analysis was also divided
according to baseline utilization. Com-
parisons are presented for nonusers at
baseline and for baseline users with one
test, two tests, or three or more tests
withinthe12monthsbeforetheinitiation
of the program. Care-managed patients
withnotestsatbaselineexperiencedasig-
niﬁcant increase in the number of A1C,
lipid,andmicroalbuminuriatestsandret-
inal examinations performed (0.75 for
A1C, 0.67 for lipid, 0.14 for microalbu-
min, and 0.54 for retinal examination; all
with P  0.001). The pattern was more
complex among baseline users. The gen-
eral pattern that emerged was that care-
managed baseline users with one test at
baseline experienced increases in A1C
and lipid testing compared with baseline
users who were not care managed. Con-
versely,care-managedbaselineuserswith
more than two tests experienced signiﬁ-
cant decreases in test utilization com-
pared with baseline users who were not
care managed.
CONCLUSIONS—Many chronically
ill individuals fail to adhere to recom-
mended medication and testing regi-
mens. This article demonstrates that,
among patients with diabetes, telephonic
diseasemanagementimprovedadherence
toboth.Althoughtherehavebeenstudies
of type 2 diabetes that have addressed ad-
herence to hypoglycemic medications
(21) and studies that have looked at ad-
herence to recommended tests and
screenings(22,23),thisstudyisuniquein
that it looked at both to create a broader
view of treatment adherence. Another
distinguishing feature of this study is that
it is the ﬁrst to our knowledge that evalu-
ated the association between participa-
tion in telephonic disease management
and treatment adherence among Medic-
aid beneﬁciaries with diabetes.
Our ﬁndings indicate that care-
managed patients increased their drug
utilization compared with matched con-
trol subjects. First, patients who ﬁlled no
prescriptions for a hypoglycemic agent,
an ACEI, an ARB, or a statin during the
year before being care managed were
more likely to initiate treatment. That is,
they were more likely than patients who
did not receive care management to ﬁll at
least one prescription. Second, even
though care management increased the
odds of initiating treatment among pa-
tients who had ﬁlled at least one prescrip-
tion for a hypoglycemic agent, an ACEI,
an ARB, or a statin in the year before, the
number of prescriptions ﬁlled during the
study period remained low on average.
The notable exception to this pattern was
insulin treatment. Insulin utilization and
adherence increased signiﬁcantly among
baseline users. This result is particularly
important, as it probably applies to pa-
tients who typically have more severe
diabetes.
Care management also affected re-
ceipt of laboratory tests and screenings.
Patients who had no test at baseline were
more likely to have at least one test per-
formed during the follow-up period. In
contrast, compared with non–care-
managed patients, care-managed patients
whohadtwoormoretestsatbaselinehad
fewer tests performed during follow-up.
This may indicate that baseline test users
received unnecessary tests at baseline and
that care management reduced the use of
unnecessary services.
The analysis also has limitations.
First,assignmenttotreatmentandcontrol
groupswasnotrandom,andbeneﬁciaries
were allowed to opt out of the program.
Although differences in baseline values
between members of the treatment and
controlgroupsweresmall,thesedifferences
could, in principle, bias our estimates.
However, as we relied on a difference-in-
differences estimator, it is the change in
the values of predictors and outcomes
that matters. The key issue is whether
there is any evidence that disease and uti-
lization trajectories over time among the
treatment group would have been differ-
ent from those of control subjects in the
absence of treatment. Careful review of
baseline values indicated that observed
differencesbetweengroupswerenotlarge
enough to suggest different disease pro-
gression trajectories and are therefore un-
likely to have introduced signiﬁcant bias.
Second,thereisacertaindegreeofimpre-
cision regarding diagnoses in claims data,
as physicians rarely record the full ﬁve
digitsofdiabetesdiagnoses,andwecould
not perform a separate analysis on type 1
and type 2 diabetic patients to determine
whether the observed increase in adher-
ence to insulin among baseline users
might be attributable to one of these
groups.
A key question given the exclusion
criteria used to create our sample is
whether our results can be generalized to
all diabetic patients in this Medicaid pop-
Table 4—Laboratory tests: changes in utilization
n*
Care managed
vs. not care
managed† P value
Patients with 0 tests at baseline
A1C 844 0.75 0.001
Lipid panel 879 0.67 0.001
Microalbumin test 2,196 0.14 0.001
Retinal examinations 1,407 0.54 0.001
Patients with 1 test at baseline
A1C 686 0.42 0.001
Lipid panel 754 0.33 0.001
Microalbumin test 317 0.47 0.001
Retinal examinations 785 0.23 0.001
Patients with 2 tests at baseline
A1C 566 0.24 0.012
Lipid panel 536 0.40 0.003
Microalbumin test 68 1.18 0.001
Retinal examinations 224 0.41 0.001
Patients with 3 tests at baseline
A1C 501 0.96 0.001
Lipid panel 428 1.04 0.001
Microalbumin test 16 2.00 0.001
Retinal examinations 181 1.92 0.001
The difference-in-differences estimator was used here. Results are expressed as the change in utilization or
MPR in the care-managed group relative to the not–care managed group. *Number of care-managed
patients. †Number of tests received over 12 months.
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of patients (n  2,598) with patients we
excluded from analysis showed little dif-
ference in demographic characteristics
and health care utilization (available from
authors),andourresultsshouldtherefore
be generalizable.
In summary, the results reported
here are important because adherence to
recommended medication and testing
regimenscandecreasemicro-andmacro-
vascular complications (2) and elevated
A1C and LDL levels (3,24), lower hospi-
talization rates (25) and health care costs
(6), and decrease cardiovascular disease–
relateddeaths(5).Thisstudyprovidesev-
idence that care management can be
effective in encouraging patients to use
hypoglycemic and cardiovascular medi-
cations as prescribed and in teaching pa-
tients to seek recommended laboratory
tests and retinal eye examinations appro-
priately. It is also important to note that
FAHS was designed for a particularly dif-
ﬁcult-to-reach chronically ill population
that accounts for a signiﬁcant share of
Florida’s Medicaid expenditures and that
even in populations with such complex
conditions telephonic care management
can be effective in changing behaviors.
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